The EMA approved Nabriva Therapeutics’ (NASDAQ:NBRV) XENLETA for the treatment of community-acquired pneumonia. The approval is based on efficacy data from two Phase 3 clinical trials, both of which established XENLETA...
Tag - NBRV
Reporting on the healthcare industry’s corporate and clinical developments, executive moves and views from the Street.
Copyright © 2020 BioTuesday Publishing Corporation - Privacy Policy